Phathom Pharmaceuticals, Inc. PHAT Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $180.9M-14.8% | $129.97M-56.3% | $135.16M-59.6% | $149.57M-45.9% | $212.32M-34.1% | ||
| $2.86M0.0% | $2.86M0.0% | $2.86M0.0% | $2.86M0.0% | $2.86M-0.2% | ||
| $265.9M+148% | $221.54M+197% | $182.21M+387% | $147.47M+800% | $107.09M+1,841% | ||
| $88.58M+84.9% | $92.52M+178% | $83.33M+178% | $65.41M+173% | $47.9M+184% | ||
| $51.64M-19.8% | $56.26M-12.2% | $61.77M+9.5% | $63.52M+16.8% | $64.4M+35.2% | ||
| $276.57M+4.4% | $228.97M-36.4% | $207.78M-44.4% | $218.88M-28.2% | $264.9M-22.2% | ||
| $1.02M-25.0% | $1.06M-27.9% | $1.16M-30.2% | $1.24M-31.5% | $1.35M-31.0% | ||
| $2.51M+546% | $2.6M+325% | $2.69M+223% | $873K-16.9% | $388K-69.3% | ||
| $3.09M+82.4% | $2.92M+72.3% | $1.69M+0.1% | $1.69M+0.1% | $1.69M+0.1% | ||
| $305.12M+3.7% | $259.15M-31.5% | $240.29M-37.9% | $250.22M-21.7% | $294.21M-17.5% | ||
| $6.37M-45.2% | $4.98M-52.6% | $1.08M-84.9% | $4.01M-47.6% | $11.62M+38.2% | ||
| —— | $7.5M-85.9% | $65.35M+82.7% | $64.3M+136% | $43.03M+160% | ||
| $33.02M+91.2% | $27.25M+37.8% | $24.34M+20.6% | $21.53M+117% | $17.27M+4.8% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $667K+111% | $648K+29.3% | $591K-13.1% | $238K-66.9% | $316K-56.7% | ||
| $347.9M+1.2% | $350.12M+5.1% | $348.98M+8.2% | $347M+8.0% | $343.81M+13.6% | ||
| $1.68M-7.0% | $1.83M+7.1% | $1.76M+15.9% | $1.76M+23.2% | $1.8M+37.9% | ||
| $125.04M+68.9% | $132.04M+54.0% | $93.12M+42.6% | $91.82M+95.3% | $74.03M+70.3% | ||
| $163.68M-19.5% | $209.09M+3.8% | $207.09M+17.8% | $205.14M+17.6% | $203.25M+36.4% | ||
| $1.96M— | —— | —— | —— | —— | ||
| $2.63M+732% | $2.71M+442% | $2.71M+299% | $827K-3.0% | $316K-69.1% | ||
| $3.5M-69.6% | $4M-65.2% | $11.5M+7.0% | $11.5M+10.0% | $11.5M+18.6% | ||
| $642.08M+1.5% | $697.32M+10.4% | $662.82M+15.4% | $656.05M+18.6% | $632.58M+25.3% | ||
| $7K+16.7% | $6K0.0% | $6K0.0% | $6K+20.0% | $6K+20.0% | ||
| $1.18B+15.6% | $1.05B+3.6% | $1.04B+3.9% | $1.03B+18.2% | $1.02B+18.1% | ||
| -$1.51B-11.6% | -$1.48B-17.5% | -$1.46B-23.1% | -$1.43B-29.9% | -$1.36B-34.2% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$336.96M+0.4% | -$438.17M-72.8% | -$422.53M-126% | -$405.83M-73.6% | -$338.38M-128% | ||
| $305.12M+3.7% | $259.15M-31.5% | $240.29M-37.9% | $250.22M-21.7% | $294.21M-17.5% | ||
| $3.09M+82.4% | $2.92M+72.3% | $1.69M+0.1% | $1.69M+0.1% | $1.69M+0.1% | ||
| $2.51M+546% | $2.6M+325% | $2.69M+223% | $873K-16.9% | $388K-69.3% | ||
| $2.51M+546% | $2.6M+325% | $2.69M+223% | $873K-16.9% | $388K-69.3% | ||
| $3.09M+82.4% | $2.92M+72.3% | $1.69M+0.1% | $1.69M+0.1% | $1.69M+0.1% | ||
| $2.51M+546% | $2.6M+325% | $2.69M+223% | $873K-16.9% | $388K-69.3% | ||
| $3.09M+82.4% | $2.92M+72.3% | $1.69M+0.1% | $1.69M+0.1% | $1.69M+0.1% | ||
| $347.9M+1.2% | $350.12M+5.1% | $348.98M+8.2% | $347M+8.0% | $343.81M+13.6% | ||
| $83.32M+93.6% | $89.83M+68.8% | $65.35M+82.7% | $64.3M+136% | $43.03M+160% | ||
| $83.32M+93.6% | $89.83M+68.8% | $65.35M+82.7% | $64.3M+136% | $43.03M+160% | ||
| —— | —— | —— | —— | —— | ||
| $347.9M+1.2% | $350.12M+5.1% | $348.98M+8.2% | $347M+8.0% | $343.81M+13.6% | ||
| $347.9M+1.2% | $350.12M+5.1% | $348.98M+8.2% | $347M+8.0% | $343.81M+13.6% | ||
| $166.3M-18.3% | $211.8M+4.9% | $209.81M+18.9% | $205.97M+17.5% | $203.56M+35.7% | ||
| $1.18B+15.6% | $1.05B+3.6% | $1.04B+3.9% | $1.03B+18.2% | $1.02B+18.1% | ||
| $7K+16.7% | $6K0.0% | $6K0.0% | $6K+20.0% | $6K+20.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Phathom Pharmaceuticals, Inc.'s total assets?
- Phathom Pharmaceuticals, Inc. (PHAT) holds $305.1M in total assets, up 3.7% year over year.
- How much debt does Phathom Pharmaceuticals, Inc. have?
- Phathom Pharmaceuticals, Inc. carries $166.3M in total debt against -$337.0M of shareholders' equity, a debt-to-equity ratio of 5.64.
- How much cash does Phathom Pharmaceuticals, Inc. have?
- Phathom Pharmaceuticals, Inc. holds $180.9M in cash and equivalents.
- Can Phathom Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 2.21 — current assets exceed current liabilities.
- Where does Phathom Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Phathom Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
